BIBF 1120 and angiogenesis inhibition

Carlos Gil Ferreira

Interview with Carlos Gil Ferreira, MD, PhD

Director Clinical and Translational Research, Instituto Nacional de Câncer

Rio de Janeiro, Brazil

Angiogenesis is critical for tumour development and tumour maintenance. New vessels
that are required by the tumour so that it can grow in a limited condition. That is the characteristic of
tumour cells. What we have learned is that, by blocking this angiogenesis, these new vessels, you can
really stop the tumour growth in some situations. That has been proved some years ago by a first class
of these inhibitors that are special antibodies, what we call ‘monoclonal antibodies’ that block the ligands
that activate those receptors. But there is a new generation now that blocks not only this receptor in the
tyrosine kinase residue, but blocks other receptors that are important also for angiogenesis and, by doing
that, we have an enhanced antiangiogenic effect. BIBF 1120 is one of those drugs that is in this new class
of angiogenesis inhibitors, so probably will also be a drug that will have a major impact in the future.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on